Survey
* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project
Chemoradiotherapy for Rectal cancer Dr. A . Sun Myint Lead Clinician GI Tumour Group Clatterbridge Centre for Oncology Association of Coloproctology of Great Britain and Ireland M62 Coloproctology Course - March 23rd 2007 Background • • • • • • In the UK over 10,000 new rectal cancer Five year survival 50% (NBOCAP-2006) Nearly half will develop recurrences At presentation 30% T3/T4 N + MO Preoperative radiotherapy reduce LR So far, no survival advantage Treatment Options Options • Surgery • Radiotherapy • Chemotherapy Improvements TME / Training Sub specialisation Pre operative Chemoradiotherapy Post operative Advance /metastatic Adjuvant New agents Radiotherapy Preoperative Radiotherapy Short course or Long course? • Short course • Long course Preoperative Radiotherapy Short course or Long course? • Short course - Mobile operable tumour • Long course - Fixed / Tethered tumour 30%( MRI defined CRM +) Preoperative Radiotherapy Short course or Long course? • Short course - Mobile operable tumour • Long course - Fixed / Tethered tumour ( MRI defined CRM +) Improving Outcomes • Add chemotherapy to radiation • Increase radiation dose Chemo-radiotherapy Concurrent Chemotherapy + RT • • • • • 5FU 5FU / FA 5FU infusion + Irino / Oxaliplatin Capecitabine + Irino / Oxaliplatin+ EGFR Capecitabine + Irino / Oxaliplatin+ VEGFR Oxaliplatin is a radiosensitiser in HT-29 xenograft models Tumour volume 160 Control 120 Oxaliplatin 5mg/kg 80 Radiation only (5Gy) 40 Oxaliplatin + radiation 0 01 05 09 13 17 Days post-treatment 21 Blackstock A et al. Int J Rad Oncol Biol Phys 2000;16:92–94 Comparative tumor sterilization rate by treatment modality Treatment modality pCR + pMic RO EBRT alone 7.1% (26%) 40% EBRT+ chemo 16.2% (31%) 60% EBRT+ duplet 21% (60%) 90% Is chemo-Radiotherapy better than RT alone? EORTC Rectal cancer trial T3/T4 rectal cancer n=1011 Pre-op RT SURGERY Pre-op Chemo/RT SURGERY Pre-op RT SURGERY Adjuvant Chemo Pre-op Chemo/RT SURGERY Adjuvant Chemo EORTC Rectal cancer trial Local recurrence Pre-op Chemo/RT Pre-op RT 8.7% 17% (p=0.0016) Bossett al ASCO 2005 EORTC Rectal cancer trial Adjuvant Chemo Survival Bossett al ASCO 2005 67.2% No Adjuvant Chemo 63.2% FFCD 9203- Rectal cancer trial T3/T4 rectal cancer n=733 Pre-op RT SURGERY Pre-op CRT SURGERY JP Gerard et al ASCO 2005 Ad Chemo Ad Chemo FFCD 9203- Rectal cancer trial Pre-op Chemo/RT Local recurrence 8.0% JP Gerard et al ASCO 2005 Pre-op RT 16.5% FFCD 9203- Rectal cancer trial Adjuvant Chemo Survival 67% JP Gerard et al ASCO 2005 No Adjuvant Chemo 66% Chemo RT vs. Radiotherapy Local control in T3/T4 rectal cancer Trials Pre-op CRT Pre-op RT EORTC 22921 8.7% 17.1% FFCD 9203 8% 16.5% German-94 6% Pre-operative Radiotherapy better than post op RT? German pre op. vs. post operative chemoradiotherapy for rectal cancer Preoperative Chemo-RT Surgery Surgery Post operative Chemo-RT Sauer et al N Engl J Med (2004) 351;17 1731-01740 German pre op. vs. post operative chemoradiotherapy for rectal cancer Pre op Local recurrence Survival Post op n=405 n=394 6% 13% P=0.0006 76% 74% P=0.08 Sauer et al N Engl J Med (2004) 351;17 1731-01740 German pre op. vs. post operative chemoradiotherapy for rectal cancer Pre op Acute Toxicity Late Toxicity Post op n=405 n=394 27% 40% P=0.001 14% 24% P=0.01 Sauer et al N Engl J Med (2004) 351;17 1731-01740 Newer agents for chemoradiotherapy Chemoradiotherapy • • • • • • • 5FU bolus 5FU+ FA Infusional 5FU Capecitabine Irinotecan +Cape Oxaliplatin +Cape Triplet therapy R A D I O T H E R A P Y NWCCOG 1+ RICE CORE/ SOCRATES Ir/Oxali + MdG+ VEGF Pre-operative 5-FU chemoradiation: • 5-FU-based chemoradiation has become part of standard pre-operative therapy for rectal cancer – effective downstaging – 10–30% pCR rates • Protracted infusion of 5-FU with postoperative radiotherapy improves survival versus bolus 1 5-FU 1O’Connell MJ et al. N Engl J Med 1994;331:502–7 Infused versus bolus 5-FU during pelvic radiation Overall survival (%) Infused 5-FU (n=328) 100 Bolus 5-FU (n=332) 80 60 Log rank p=0.005 Cox model p=0.01 40 20 0 0 1 2 3 4 Years after randomisation O’Connell MJ et al. N Engl J Med 1994;331:502–7 Capecitabine + radiation capecitabine plus radiotherapy • Infused 5-FU is cumbersome and inconvenient for patients • Oral capecitabine simplifies chemoradiation and is highly appealing to patients • Potential for enhanced therapeutic ratio – capecitabine generates 5-FU preferentially in 1 tumour via thymidine phosphorylase (TP) – radiotherapy further upregulates TP in tumour 1Miwa 2Sawada 2 M et al. Eur J Cancer 1998;34:1274–81 N et al. Clin Cancer Res 1999;5:2948–53 Irradiation upregulates TP TP (units/mg protein) 5Gy 25 2.5Gy * 20 Control * 15 * * 10 * 5 * * * * 0 0 *p<0.05 3 6 9 12 15 Days after X-ray irradiation 18 21 Sawada N et al. Clin Cancer Res 1999;5:2948–53 capecitabine enhances activity of radiation in WiDr xenografts, Tumour inhibition (%) 120 * 100 80 60 40 20 0 *p<0.05 Sawada N et al. Clin Cancer Res 1999;5:2948–53 Capecitabine chemoradiation: • Oral capecitabine is replacing 5-FU in chemoradiation – capecitabine is highly effective and well tolerated in combination with radiotherapy – capecitabine simplifies chemoradiation and is highly appealing to patients and clinicians alike Chemoradiation in rectal cancer: German phase II study (n=68) Day 1 8 15 22 29 35 50.4Gy radiotherapy 1.8Gy / fraction 825mg/m2 twice daily Continuous (days 1–37) • Male / female (%)63 / 37 • Median age 65 years • ECOG 0/1 (%) 54 / 41 • T3 / T4 (%)48 / 52 (57% N1–3) Dunst J et al. Proc Am Soc Clin Oncol 2003;22:277 (Abst 1113) capecitabine chemoradiation:efficacy Patients (%) 1 2 Dunst study Lin study Down staging 79 73 pRR 80 87 pCR 5 20 1Dunst 2Lin J et al. Eur J Cancer 2003;1(Suppl. 5):S86 (Abst 282) E et al. Proc Am Soc Clin Oncol 2003;22:287 (Abst 1152) capecitabine chemoradiation: Toxicity Patients (%) 80 • No grade 4 adverse events 60 Grade 1/2 40 Grade 3 20 0 Diarrhoea Local erythema Pain Hand-foot syndrome Nausea Dunst J et al. Eur J Cancer 2003;1(Suppl. 5):S86 (Abst 282) NSABP R-04 rectal cancer trial Objectives – – – – DFS recurrence rate pCR safety capecitabine continuously throughout radiotherapy (50.4Gy*) Resectable rectal cancer, stage II–III n=1600 5-FU continuous infusion throughout radiotherapy (50.4Gy*) *Plus 5.4Gy for fixed tumours S U R G E R Y Chemoradiation using Oxaliplatin combination capecitabine/oxaliplatin chemoradiation Patients (%) Glynne-Jones (n=16) 1 2 Rödel (n=31) pCR 31 19 pT1 / 2N0 19 23 R0 88 94 R1 12 6 Resection margin 1Glynne-Jones R et al. Proc Am Soc Clin Oncol 2003;22:292 (Abst 1174) 2Rödel C et al. J Clin Oncol 2003;21:3098–104 CORE: European study Day 1 8 15 22 29 Radiotherapy 45Gy / 25 fractions capecitabine 825mg/m twice daily Monday to Friday 2 Oxaliplatin 50mg/m weekly 2 CORE: Capecitabine, Oxaliplatin, Radiotherapy and Excision Chemoradiotherapy using Irinotecan combination RICE - NWCCOG study Day 1 8 15 22 29 Radiotherapy 45Gy / 25 fractions capecitabine 825mg/m twice daily Monday to Friday 2 IRINOTECAN 60mg/m2 weekly S. Gollins, S.Myint, E. Levine et al Proc Am Soc Clin Oncol 2006;24:617s (Abst 13519) Chemoradiotherapy • • • • • • • 5FU bolus 5FU+ FA Infusional 5FU Capecitabine Irinotecan +Cape Oxaliplatin +Cape Triplet therapy R A D I O T H E R A P Y NWCCOG 1+ RICE CORE/ SOCRATES Ir/ Oxali + cape+ EGF ARISTOTLE Reducing Toxicity from CRT Toxicity • • Chemoradiotherapy is more toxic than radiotherapy alone To reduce toxicity:Preoperative rather than post op Radiation volume Dose, fractionation and time Radiation techniques Are there any other options to reduce toxicity from chemoradiation? Improving Outcomes • Add chemotherapy to radiation • Increase radiation dose Increasing Radiation dose • External Beam ( 45 Gy /25# /35) • EBRT +Boost ( 50.4Gy/28#/38) • EBRT + Contact RT boost (60-80Gy) • EBRT + Contact HDR boost Papillon Technique Radical contact radiotherapy Lyon R96-02 Trial Results EBRT Clinical CR ( 2% ) Path CR/micro (34%) Sphincter (44%) EBRT+ boost (24%) (57%)p=.027 (76%)p=.004 JP Gerard et al. J Clin Oncol 2004 :22 2404-2409 Lyon R96-02 Trial Results EBRT LR Morbidity LR Survival 3% 43% 88% EBRT + Boost 1% 38% 92% JP Gerard et al J Clin Oncol 2004 :22 2404-2409 HDR Rectal Brachytherapy 20mm 5mm Pre op HDR Brachytherapy Pathology • • • • T0N0 Micro Residual N+ 29% 37% 34% 31% • T. Vuong et at. I.J. Rad Onc. Bio. Phys vol60:no1 supp; 2004 abst: 1062 Pre op HDR Brachytherapy Results • Median FU 37months • 5years Local recurrence DFS OS CSS • Toxicity G3 3% 65% 74% 84% 1% (30% CRT) T. Vuong et at. I.J. Rad Onc. Bio. Phys vol60:no1 supp; 2004 abst: 1062 Comparative tumor sterilization rate by treatment modality TREATMENT pCR (pMic) RO EBRT alone 7.1% (26%) 40% CT+ EBRT 13% (31%) 60% EBRT+contact 21% (60%) NA HDR alone 29% (66%) 97% CT+EBRT+ HDR boost 40%? (80%) 100? Treatment Options • Surgery T1/T2/T3 / N+ (clear CRM) • Pre op chemo RT r CRM <1mm (sphincter preservation) • Post op chemo RT p CRM<1mm (node +ive) • Radical RT T1/T2/ N0 Conclusions-1 • All cases with rectal cancer should be discussed at the MDT • MRI scan is essential for pre operative assessment • Pre operative chemoradiotherapy offers better local control than pre operative radiotherapy alone Conclusions-2 • Pre operative chemoradiotherapy is more effective and less toxic than post operative chemoradiotherapy • Nearly half the patients with rectal cancer will develop recurrences; however no DFS or overall survival benefit has been shown with adjuvant chemotherapy in any of the trials published so far. It is important to contribute to clinical trials